LSL Pharma Group Inc. (TSXV: LSL) reported its fourth consecutive record quarterly revenues and solid year-to-date (YTD) performance for the 2025 fiscal year, ended September 30, 2025. All figures are in thousands of Canadian dollars.
“We achieved record revenues in Q3-25 for the fourth consecutive quarter reflecting the contribution of Dermolab acquired late last year. By acquiring Du-Var Laboratory, we can already project good growth of our CMO segment for the next year,” stated Francois Roberge, President and CEO of LSL Pharma. “With the first 6 eye-drops now approved by Health Canada we are well positioned to execute our strategic plan for 2026, as we approach the FDA decision regarding the certification of our Steri-Med site to manufacture Avaclyr and other products for the US market.”
The company notes ongoing leverage from recent acquisitions and regulatory progress as it positions for expanded manufacturing capabilities and potential US market entry in 2026.
Author’s summary: LSL Pharma reports continued strong growth through 2025, aided by Dermolab and Du-Var acquisitions, with regulatory milestones paving the way for 2026 expansion.